1 not yet recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Cyllene Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Urodynamics, EG110A, Patient-reported Outcome - Urinary Bladder, Overactive, Spinal Cord Injury | Phase 1 / Phase 2 | Not yet recruiting | Cyllene Therapeutics | 16 | 2026-04-01 | 2025-11-12 |
| Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization EG110A - Neurogenic Detrusor Overactivity, Spinal Cord Injuries | Phase 1 / Phase 2 | Recruiting | Cyllene Therapeutics | 16 | 2025-01-08 | 2026-09-03 |
Spinal Cord Injuries (2) · Urinary Bladder, Overactive (1)
Patient Reported Outcome Measures (1) · Urodynamics (1)
United States (2)